14 Dez 2023 | Press release
TechnoPhage, a clinical-stage biopharmaceutical company specializing in the development of phage treatments targeting specific pathogenic bacteria, has announced, following the successful conclusion of the Phase 1 study in 2022, the initiation of Phase 2b study...
28 Nov 2023 | Sem categoria
We are thrilled to announce that Technophage has been recognized by IAPMEI, I.P. – Agência para a Competitividade e Inovação (Agency for Competitiveness and Innovation) with the prestigious ‘PME Líder’ distinction for the year 2023! This...
